Neovascular Age-Related Macular Degeneration in the Very Old (≥90 Years): Epidemiology, Adherence to Treatment, and Comparison of Efficacy

Table 4

Two-year results on Ranibizumab treatment for neovascular age-related macular degeneration in patients aged ≥90 years.

	Ranibizumab ()
	Mean (95% CI)	P value
ΔBCVA, ETDRS letters
4 months	1.2 (−3.0 to 5.3)	0.570
12 months	−0.5 (−4.8 to 3.7)	0.800
24 months	−5.8 (−10.9 to −0.6)	0.028
Δ average CRT, μm
4 months	−114 (−155 to −73)	<0.001
12 months	−95 (−138 to −52)	<0.001
24 months	−98 (−143 to −52)	<0.001

BCVA: best-corrected visual acuity; CRT: central retinal thickness; CI: confidence interval. values were calculated using the one sample t-test with test value = 0.